CD274 and neoplasm: Consistently, in preclinical models as well as in clinical trials, chemotherapeutic regimens based on well-established ICD inducers including anthracyclines and oxaliplatin synergize with antibodies blocking the PD-1-PD-L1 interaction to enhance T cell infiltration, delay cancer progression, and generate long-term immune memory against tumor-associated antigens.1